Cargando…

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study

BACKGROUND: Direct-acting antivirals have been used for decompensated cirrhotic patients with hepatitis C virus (HCV) infection. However, the benefits in Chinese patients with decompensated cirrhosis are unclear. METHODS: Thirty patients with HCV infection and decompensated cirrhosis were administer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Fanpu, Wang, Wenjun, Dang, Shuangsuo, Wang, Shengbang, Li, Burong, Bai, Dan, Zhao, Wenxue, Deng, Hong, Tian, Changyin, Li, Zongfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598030/ https://www.ncbi.nlm.nih.gov/pubmed/28924449 http://dx.doi.org/10.1186/s13027-017-0158-1

Ejemplares similares

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis
por: Wei, Bin, et al.
Publicado: (2018)

Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
por: Ji, Fanpu, et al.
Publicado: (2013)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia
por: Murayama, Aiko, et al.
Publicado: (2021)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis
por: Sakamori, Ryotaro, et al.
Publicado: (2021)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety
por: Hayward, Kelly L., et al.
Publicado: (2021)

Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review
por: Zhao, Wenxue, et al.
Publicado: (2013)

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort
por: Kwo, Paul, et al.
Publicado: (2018)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

The Association Between Decompensated Liver Cirrhosis and Deep Neck Infection: Real-World Evidence
por: Tsai, Ming-Shao, et al.
Publicado: (2019)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Seasonality of cellulitis: evidence from Google Trends
por: Zhang, Xin, et al.
Publicado: (2018)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
por: Han, Qunying, et al.
Publicado: (2019)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study
por: Fan, Xiaoli, et al.
Publicado: (2018)

Improving Survival in Patients with Decompensated Cirrhosis
por: Amarapurkar, Deepak, et al.
Publicado: (2011)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study
por: Hannah, Nicholas, et al.
Publicado: (2023)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Real‐world treatment outcomes of sofosbuvir‐based regimens for treatment of chronic hepatitis C with and without human immunodeficiency virus co‐infection
por: Khemnark, Suparat, et al.
Publicado: (2023)

Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
por: Sarwar, Shahid, et al.
Publicado: (2017)

Treatment of Hepatitis B in Decompensated Liver Cirrhosis
por: Guan, Richard, et al.
Publicado: (2011)

Prescribing Medications in Patients with Decompensated Liver Cirrhosis
por: Amarapurkar, Deepak N.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hqessf97mpuu02qae8a9kut1s1